Northwest Biotherapeutics reported $-14.32M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Agenus USD 14.4M 19.26M Dec/2025
AstraZeneca USD 7.11B 4.14B Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celldex Therapeutics USD -84.44M 2.72M Mar/2026
Eisai JPY -10.31B 30.35B Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Northwest Biotherapeutics USD -14.32M 481K Sep/2025
Pfizer USD 4.99B 340M Mar/2026
Plus Therapeutics USD -5.74M 1.26M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025